Combined Treatment for Non-Healing Wounds in Chronic Lower Extremity Arterial Disease: A Comparative Study
Key facts
- Who runs it
- Tulip Medicine
- Where
- Kazakhstan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 116 people enrolled
- Started
- 9 Jan 2023
- Ended
- 6 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- balloon angioplasty and stenting of lower extremity vessels + fibroblasts
- balloon angioplasty and stenting of lower extremity vessels
- Record updated
- 1 October 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Male and female patients aged 18 to 75 years inclusive
- Patients with a history of confirmed stable intermittent lameness, the symptoms of which have been observed continuously for at least 3 months at the time of randomization
- Patients with a diagnosis of PAD (code I 70.2 - I 70.9 according to the International Classification of Diseases, 10th revision [ICD - 10]), confirmed by the results of ultrasound duplex scanning of blood vessels
- Patients whose smoking status remained stable for at least 3 months prior to randomization (for smokers)
- Patients with an ankle - brachial Doppler index value at rest ≤0.9
- Patients with a long-term non-healing wound (more than 1 month) and intermittent claudication with a pain-free walking distance of less than 200 meters
- Patients who, in the opinion of the investigator, are able to understand and comply with the study requirements
- Before starting any examination procedures by the patient or, if applicable, its legal representative, a signed and dated written informed consent form, as well as any necessary processing permissions personal data
Who cannot take part
- Patients who underwent reconstructive intervention on the arteries of the lower extremities (surgical or intravascular) in the last 3 months before randomization
- Patients who underwent major cardiac surgery within 6 months prior to randomization
- Progression of the underlying and concomitant disease
- Acute myocardial infarction (ACS), acute cerebrovascular accident (stroke)
- Acute infectious diseases
- Patients with congestive heart failure III-IV functional class according to classification of the New York Heart Association
- Patients with any other disease that significantly limits physical activity, or any other medical condition that, in the opinion of the investigator, may limit the patient's participation in the study
- Patients with mental status disorders
- Patients with a history of hypersensitivity or allergy to a radiopaque substance, similar drugs or excipients
- Presence of peptic ulcer of the stomach and duodenum (DUD)
- Patients with total thrombosis of the vessels of the lower extremities
- High levels of creatinine and urea in a biochemical blood test (creatinine in women: more than 80.0 µmol / l; men: more than 110.0 µmol / l; ); ( Urea in adults under 60 years of age is more than 8.32 mmol/l, adults over 60 years of age are more than 7.5 mmol/l )
- Pulmonary embolism (PE)
- Patients who are pregnant or breastfeeding, or who plan to become pregnant before participating in this study or during the study, or who intend to become an egg donor within the same period of time
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Endovascular interventions, such as balloon angioplasty and stenting, are commonly used for PAD due to their proven safety and effectiveness. However, traditional treatments for chronic non-healing wounds are often insufficient. Advances in cell biotechnology, particularly fibroblast therapy, show promise for enhancing wound healing, as fibroblasts play a crucial role in tissue repair and inflammation.
Read full original descriptionShow less
This study aims to develop, assess, and evaluate the safety of a combined treatment approach that incorporates fibroblast therapy with existing methods for managing chronic non-healing wounds in PAD patients.
The 2 groups in the trial
- combined treatmentTreatment being tested
Combined treatment (balloon angioplasty or stenting + fibroblast transplantation).
Treatment: balloon angioplasty and stenting of lower extremity vessels + fibroblasts
- Endovascular treatmentExisting treatment, for comparison
Endovascular interventions + traditional debridement.
Treatment: balloon angioplasty and stenting of lower extremity vessels
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effectiveness of Combined Treatment Methods for Non-Healing Wounds in Patients With Chronic Lower Extremity Arterial Disease: A Comparative Study
- Record updated
- 1 October 2026